维莫非尼联合BH3模拟物Navitoclax治疗BRAF突变甲状腺癌
该研究在BRAFV600E阳性甲状腺乳头状癌细胞系K1中观察维莫非尼对BCL-2家族抗凋亡蛋白表达的影响,并评估维莫非尼联合BCL-2/BCL-XL抑制剂navitoclax的细胞毒作用。结果显示维莫非尼处理后BCL-XL和BCL-2表达升高,联合低剂量navitoclax可显著增强对细胞生长的抑制并增加凋亡。
要点
- 维莫非尼10 μM使K1细胞生长抑制49.4%。
- 维莫非尼处理后p-ERK1/2下降但BCL-XL和BCL-2表达升高。
- 0.5 μM navitoclax联合1 μM维莫非尼显著增强生长抑制和凋亡。
核心结论
- 维莫非尼处理可上调BRAFV600E阳性PTC细胞中BCL-2家族抗凋亡蛋白表达。
- 维莫非尼联合navitoclax可能对BRAFV600E阳性PTC具有更好疗效。
研究设计与样本
- 体外细胞研究,使用BRAFV600E阳性人甲状腺乳头状癌细胞系K1。
- 以不同浓度维莫非尼处理,分析p-ERK1/2和抗凋亡BCL-2家族蛋白表达,并评估navitoclax单用及联合维莫非尼的细胞毒作用。
主要发现
- 10 μM维莫非尼抑制K1细胞生长49.4%。
- 10 μM维莫非尼处理后p-ERK1/2在24小时内逐渐下降,而BCL-XL和BCL-2表达在12小时后升高。
- 单用navitoclax至4 μM处理24小时对细胞存活影响可忽略。
- 0.5 μM navitoclax联合1 μM维莫非尼显著增强细胞生长抑制并增加凋亡。
临床怎么用
- BRAFV600E阳性PTC中,BRAF抑制剂治疗可能上调BCL-2家族抗凋亡蛋白,联合BCL-2/BCL-XL抑制剂或可提高疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vemurafenib is a selective BRAF inhibitor (BRAFi) that has shown promising activity in BRAFV600E-positive papillary thyroid cancer (PTC). However, adverse events and resistance to a single-agent BRAFi often require discontinuation of the targeted therapy in BRAFV600E-positive PTC. Thus, this study investigated the expression of anti-apoptotic B-cell lymphoma 2 (BCL-2) family members, which are frequently overexpressed in many human cancers to inhibit apoptosis, in PTC harboring the BRAFV600E mutation after BRAFi treatment, and then evaluated the cytotoxic effects of a homology 3 domain (BH3)-mimetic in combination with a BRAFi. METHODS: K1 cells (BRAFV600E-positive human PTC) were treated with various concentrations of vemurafenib to investigate the effect of the BRAFi. In addition, the study analyzed the protein expression profiles of phosphorylated ERK1/2 (p-ERK 1/2) and anti-apoptotic BCL-2 family after vemurafenib treatment and selected the target anti-apoptotic protein. Antitumor effects were measured by cell counting, and effects on apoptosis were determined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay and Western blot analysis. RESULTS: At a concentration of 10 μM, vemurafenib inhibited the growth of K1 cells by 49.4%. Western blot analysis following exposure to 10 μM vemurafenib revealed that p-ERK1/2 gradually decreased over 24 hours, but the expression of B-cell lymphoma-extralarge (BCL-XL) and BCL-2 increased after 12 hours of treatment. Based on this result, the K1 cells were treated with navitoclax (BCL-2/BCL-XL inhibitor) for 24 hours up to a concentration of 4 μM, which resulted in negligible effects on cell survival. However, a combination treatment of 0.5 μM navitoclax with 1 μM vemurafenib resulted in significantly enhanced cell growth inhibition and increased apoptosis. CONCLUSIONS: The results of the present study show that vemurafenib increased the expression of anti-apoptotic proteins of the BCL-2 family. Thus, the combination of vemurafenib with navitoclax may be effective in BRAFV600E-positive PTC treatment.
引用
- Jeong JH, Oh JM, Jeong SY, et al. Combination Treatment with the BRAFV600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma. Thyroid. 2019. PMID: 30869573. doi:10.1089/thy.2018.0511
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。